Dependence of Indian pharmaceutical industry

Indian pharmaceuticals - a rising star in the name of the pharma industry.

India is prominent and rapidly growing in the presence of global pharmaceuticals. It is the largest provider of generic medicines around the globe and also supplies 62% of global demand for vaccines. India rates 3rd worldwide for output by volume. It manufactures about 500 different APIs. It is by calendar the only country with the most significant number of US-FDA compliant Pharma plants. India has nearly about 1500+ WHO-GMP approved Pharmaceutical Plants, 250+ European Directorate of Quality Medicines (EDQM) supported factories.

India is now the citation of 60,000+ generic brands across 60+ medicinal categories. The API sector is ranked third largest in the world. India is a hub to more than 2500 pharmaceutical companies with a strong structure of over 11500 production units. Pune, Hyderabad, Mumbai, Baddi, Himachal Pradesh, Chennai, Bangalore, Ahmedabad, Vadodara, Ankleshwar, Vapi, and Sikkim Kolkata are the major pharmaceutical centres of India.

The Government started to see the polarity of pharma. It motivated the development of drug manufacturing by Indian companies on the onset of 1960. Most pharmaceutical businesses operating in India, employ Indians almost exclusively from the meagrest positions to high-level leadership. The homegrown pharma company, are often a collaboration of private and public companies.

In terms of the international market, India holds captive share and is known as the pharmacy of the world. India is the most significant contributor in UNESC with over 50-60% share.

So after such achievement, why is India's dependency on foreign counties?

DEPENDENCE ON OTHER COUNTRY FOR API

The global pharma industry is dependent on China for raw material supplies. India imports 69-70%/of API from China, which amounts to a total of 2.4 billion dollars. These imports are used to manufacture fundamental medicines like paracetamol, metronidazole, ampicillin, and amoxicillin, etc. Supply disruptions occurred earlier during 2008; units were shut down over environmental concerns. A similar event took place in 2018. Significantly, these shocks boost India's API exports, which account for 20 billion dollars. Even so, the Centre has acknowledged the need for self-sufficiency in APIs.

China's cost of manufacturing is way cheaper than India's. Unfortunately, the Budget overlooked this aspect. The now-struggling Indian Pharmaceuticals Ltd should take a step in producing essential APIs. Its role in increasing the production rate of tetracycline during the 1994 plague is enlightening in this concern. At the same time, the lowering in exports of APIs by China uncovered the world's reliance on it. India's dependency has remarkably been brought to light as it uses Chinese elements to produce one-fifth of the world's supply of medicines. Indian antibiotic manufacturers depend heavily for about close to about 90% on imports of raw materials. Granules India and Aurobindo Pharma are among the highest revelation to imports of APIs from China.

The global pharmaceutical industry is intertwined in a complicated manner, and it will slowly unfold. Still, shortages in the production of APIs in China are likely to increase. Deficiencies would affect the output of formulations across the globe.

POOR INFRASTRUCTURE OF REGULATORY BODIES

With the increase in government investment in the health care sector by the launch of Ayushman Bharat, the domestic market is expected to notice further expansion. However, that is only one aspect of the anecdote. The other hand—Indian drugs are lagging at the World Health Organisation (WHO) quality standards and also by western medicine regulating authorities like the Food and Drug Administration (FDA).

A few years back, the USFDA had found shortcomings are getting to medicine quality in India. The issue still prevails. The 'Special 301 Report' by the United States Trade Representative (USTR) railed *against* India and China as leading authorities of counterfeit medicines distributed worldwide with 20 %of all pharmaceutical products sold.

Where is India's pharmaceutical market headed?

Regulatory infrastructure must be put in place to secure worldwide quality. This does not fit well into India's status of "world's pharmacy." This makes it rather essential to put in place the regulatory infrastructure to meet global quality, and safety demands are grasped to- in all manner.

LACK OF FUNDING

The Government established the Department of Biotechnology in 1986 under the Ministry of Science and Technology. Since then, there have been several dispensations offered by both the central government and various states. They motivate the development of the industry. Yet the biotechnology sector faces some significant challenges in its quest for growth. Chief among them is a lack of funding, particularly for new firms. The most likely authorities to fund are government grants and enterprise capital, which is a relatively new industry in India. Government grants are hard to maintain. Due to the costly and unstable nature of biotech research, venture capitalists are unwilling to invest in firms that have not yet developed a commercially available product.

LACK OF RESEARCH AND DEVELOPMENT

India faces a shortage of research components and a tangible duration of good manufacturing practices. This has always been an issue for the pharmaceutical industry. There are very few skilled intelligence to uphold an entire industry. Indian pharmaceutical industry does not have very skilled talent, which also hampers the research and development work.

Opportunities in future

The enterprise should launch research policies via direct contact with a skilled researcher or faculty.
Incentives should be paid to students who are contributing to the development of any research process for the industry.
Every industry has its policy to serve the community. Therefore, the medical sector should train students.
Implementation of user-friendly policies will help people to inaugurate small scale industry and encourage stents and middle-class business owners to invest in it. This will help to conquer the problem of unemployment for pharmacists and facilitate entrepreneurship in the nation.